Becker muscular dystropy (BMD) is an inherited condition that causes progressive weakness and wasting of skeletal and cardiac (heart) muscles. It primarily affects males. The age of onset and rate of progression can vary.
Muscle weakness usually becomes apparent between the ages of 5 and 15. In some cases, heart involvement (cardiomyopathy) is the first sign. Furthermore, BMD is caused by a mutation in the DMD gene and is inherited in an X-linked recessive manner. It is very similar to Duchenne muscular dystrophy, except that in BMD, symptoms begin later and progress at a slower rate. There is no cure for this condition, but there is an ongoing research that shows significant promise in treating the disease.
COVID-19 scenario analysis
The coronavirus disease 2019 (COVID-19) pandemic has resulted in the reorganization of health-care settings affecting clinical care delivery to patients with Becker muscular dystrophy (BMD) as well as other inherited muscular dystrophies. The magnitude of the impact of this public health emergency on the care of patients with BMD is unclear as they are suspected of having an increased risk for severe manifestations of COVID-19. There is concern that patients with becker muscular dystrophy may be at an increased risk of developing multisystemic and severe complications of COVID-19, owing to major comorbidities such as chronic immunosuppression from corticosteroids, respiratory insufficiency leading to poor airway clearance and the need for long-term ventilator support, and cardiac dysfunction. Hence becker muscular dystropy market is expected to have a positive impact on the COVID-19 pandemic.
Top impacting factors: market scenario analysis, trends, drivers, and impact analysis
Rise in incidences of rare diseases, rise in R&D investments, and growth in adoption of genetic testing worldwide are some of the major drivers that propel growth of the Becker muscular dystrophy treatment market. Owing to its X-linked recessive inheritance, Becker muscular dystrophy is common in men, with the gene being obtained from carrier mother. Prevalence of the disease is considered to be approximately 17 to 27 cases per million people. This means that at a given time, about 1 in 37,000 to 1 in 59,000 people are living with BMD. Prenatal testing and genetic counseling helps in spreading awareness about disease and its inheritance, which, in turn, contributes toward rise in demand for Becker muscular dystrophy therapeutics. However, high cost of genetic testing procedures and lack of effective and specific treatment for Becker muscular dystrophy are expected to hamper growth of the global becker muscular dystropy market.
Key benefits of the report
- This study presents the analytical depiction of the global becker muscular dystropy market along with current trends and future estimations to determine imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the becker muscular dystropy market share.
- The current market is quantitatively analyzed to highlight the becker muscular dystropy market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Becker muscular dystrophy market report
- Which are the leading players active in the Becker muscular dystrophy market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What are the projections for the future that would help in taking further strategic steps
Becker Muscular Dystropy Market, by Diagnosis Report Highlights
| Aspects | Details |
 By Diagnosis |
|
 By Treatment |
|
 By End User |
|
 By Region |
|
 Key Market Players | Italfarmaco Spa, Ptc Therapeutics Inc, Sarepta Therapeutics Inc, Milo Biotechnology Llc, Reveragen Biopharma Inc |
Loading Table Of Content...
